New inhaled therapy targets tough lung infections in cystic fibrosis
Disease control
Recruiting now
This study tests an inhaled drug called RSP-1502 in people with cystic fibrosis who have a chronic lung infection caused by Pseudomonas aeruginosa bacteria. The main goal is to see if the drug is safe and how the body handles it. About 72 participants aged 12 and older will recei…
Phase: PHASE1, PHASE2 • Sponsor: Respirion Pharmaceuticals Pty Ltd • Aim: Disease control
Last updated May 26, 2026 10:17 UTC